What is the research dosage range for BPC-157?

Rodent studies used doses around 10 µg/kg and higher; researchers commonly translate these with allometric scaling to a per-administration research range of roughly 200–500 µg. These figures come from the preclinical literature and are reproduced as a laboratory research reference, not a human dosing protocol or medical advice.

How often is BPC-157 administered in research protocols?

Because BPC-157's systemic half-life is very short (under about 30 minutes), research protocols typically model daily — sometimes twice-daily split — administration rather than the weekly cadence used for long-acting peptides. Cycles of about 4–6 weeks followed by a break are a common research-modelling convention.

How do I reconstitute a 5mg BPC-157 vial?

Add bacteriostatic water to the lyophilized powder. Adding 2 mL gives 2.5 mg/mL (2,500 µg/mL), so 0.1 mL on a U-100 insulin syringe is 250 µg and 0.2 mL is 500 µg. Adding 1 mL gives 5 mg/mL and halves those volumes. Always confirm against the reconstitution calculator before any in-vitro work.

What is BPC-157's half-life?

BPC-157 has a very short reported systemic half-life — under roughly 30 minutes in plasma. That short circulating time is why research protocols favour frequent (daily or split) dosing and why localized, near-site delivery appears throughout the tissue-repair literature.

Is BPC-157 approved for human use?

No. BPC-157 has no regulatory approval for human use and its dosing evidence is overwhelmingly preclinical. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.

BPC-157 · 5mg vial · research use only

BPC-157 dosage, anchored to the research literature.

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a sequence in gastric juice, and almost all its dosing data comes from rodent studies rather than human trials. This page lays out the microgram-per-kilogram ranges the literature actually reports, how researchers translate those to a per-administration figure, the reconstitution math for a 5mg lyophilized vial, and the short systemic half-life that shapes dosing frequency — framed as a research reference, not a human protocol or medical advice.

BPC-157 5mg vial — $54.99 Reconstitution calculator

What the animal literature reports

The rodent studies that built BPC-157's reputation used doses spanning roughly 10 µg/kg up to higher microgram-per-kilogram amounts, delivered intraperitoneally, subcutaneously, or orally. Researchers commonly translate the rodent figures with allometric scaling, which lands the per-administration research range most protocols model at roughly 200–500 µg per use. The peptide's reported effects in the literature centre on tendon, ligament, muscle and gut-tissue models.

BPC-157 research overview →

Reconstitution math, 5mg vial

Titan's BPC-157 ships as a 5mg lyophilized vial. Reconstitute with bacteriostatic water: add 2 mL and you get 2.5 mg/mL (2,500 µg/mL), so a 0.1 mL draw on a U-100 insulin syringe is 250 µg and 0.2 mL is 500 µg. Add 1 mL instead for 5 mg/mL and every mark doubles. A single 5mg vial covers a typical multi-week research cycle at the ranges above — confirm against the calculator first.

Run the numbers →

Short half-life, frequent dosing

BPC-157's systemic half-life is reported as very short — under about 30 minutes in plasma — which is why research protocols typically model daily (sometimes split twice-daily) administration rather than the weekly cadence used for long-acting peptides. The short circulating life is also why localized, near-site delivery is a recurring theme in the tissue-repair literature.

BPC-157 half-life →

Cycle framing in the literature

Research protocols typically run BPC-157 in cycles of about 4–6 weeks of daily administration followed by a break, rather than continuous indefinite use. The cycle length lines up with the tissue-model timelines in the studies. These are research-modelling conventions reproduced from the literature, not a treatment schedule.

The BPC-157 / TB-500 pairing →

Format and purity to confirm

Titan's BPC-157 is a 5mg lyophilized powder with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet. With a microgram-scale dosing range, purity and identity matter more than usual — a sub-spec lot changes the effective amount delivered far more than a draw-volume rounding error would.

See the testing workflow →

Research-use framing

BPC-157 has no regulatory approval for human use and its dosing data is overwhelmingly preclinical. The ranges here are reproduced as a laboratory research reference for in-vitro and modelling work — not instructions for human use. Titan supplies BPC-157 strictly as a research reagent, and nothing on this page is medical or dosing advice.

Research-use policy →

The detail, in plain terms

The dosing reference, in one table.

BPC-157's dosing is derived from preclinical work, so the useful figures are the reported microgram-per-kilogram ranges and the per-administration amounts researchers scale them to. These are the variables a research protocol actually weighs — reproduced as a reference, not a human protocol.

Compound: BPC-157 — synthetic stable gastric pentadecapeptide (15 amino acids).
Reported range: ≈10 µg/kg in rodents; commonly scaled to ~200–500 µg per administration.
Frequency: Typically modelled daily (sometimes split) given the short half-life.
Half-life: Very short systemically — under ~30 minutes in plasma.
Format: 5mg lyophilized vial, $54.99 — reconstitute before in-vitro use.
Reconstitution: 2 mL BAC water → 2.5 mg/mL (0.1 mL = 250 µg); 1 mL → 5 mg/mL.

Questions researchers ask

Before you order.

What is the research dosage range for BPC-157?: Rodent studies used doses around 10 µg/kg and higher; researchers commonly translate these with allometric scaling to a per-administration research range of roughly 200–500 µg. These figures come from the preclinical literature and are reproduced as a laboratory research reference, not a human dosing protocol or medical advice.
How often is BPC-157 administered in research protocols?: Because BPC-157's systemic half-life is very short (under about 30 minutes), research protocols typically model daily — sometimes twice-daily split — administration rather than the weekly cadence used for long-acting peptides. Cycles of about 4–6 weeks followed by a break are a common research-modelling convention.
How do I reconstitute a 5mg BPC-157 vial?: Add bacteriostatic water to the lyophilized powder. Adding 2 mL gives 2.5 mg/mL (2,500 µg/mL), so 0.1 mL on a U-100 insulin syringe is 250 µg and 0.2 mL is 500 µg. Adding 1 mL gives 5 mg/mL and halves those volumes. Always confirm against the reconstitution calculator before any in-vitro work.
What is BPC-157's half-life?: BPC-157 has a very short reported systemic half-life — under roughly 30 minutes in plasma. That short circulating time is why research protocols favour frequent (daily or split) dosing and why localized, near-site delivery appears throughout the tissue-repair literature.
Is BPC-157 approved for human use?: No. BPC-157 has no regulatory approval for human use and its dosing evidence is overwhelmingly preclinical. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.